Latest news
BOND-003 Phase 3: Cretostimogene Shows 75% Complete Response Rate in BCG-Unresponsive NMIBC - OncodailyOncodaily · Sat, 01 Aug 2026 09:50:17 GMTImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer - ImmunityBioImmunityBio · Wed, 29 Jul 2026 07:00:00 GMTDurable Responses Seen With Cretostimogene in BCG-Unresponsive NMIBC - Targeted OncologyTargeted Oncology · Wed, 29 Jul 2026 07:00:00 GMTThe Unmet Need in BCG-Unresponsive NMIBC - Urology TimesUrology Times · Tue, 28 Jul 2026 07:00:00 GMTCretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC - OncLiveOncLive · Tue, 28 Jul 2026 07:00:00 GMT